US Government Reclassifies Cannabis to Schedule III, Unlocking Tax Relief and Research

The U.S. Department of Justice announced on Thursday the reclassification of cannabis from Schedule I to Schedule III under the DEA's controlled substances framework. While the move does not legalize the drug at the federal level, it acknowledges the medical utility of cannabis and reduces the regulatory hurdles for scientific study. This policy shift represents one of the most significant changes to federal marijuana oversight in decades. By moving cannabis out of the same category as heroin and LSD, the administration is facilitating expanded clinical trials for treating conditions such as PTSD, chronic pain, and various neurological disorders. The reclassification carries profound financial implications for the industry. Specifically, cannabis operators will now be exempt from IRS Code Section 280E, which previously prohibited them from deducting standard business expenses like payroll and rent. Additionally, the shift is expected to lower barriers for traditional banking institutions to provide services to the sector. The administration will immediately move state-licensed medical products and FDA-approved marijuana items to Schedule III, with a formal hearing scheduled for June to consider full federal reclassification. Industry experts suggest that while the state-by-state legal landscape remains fragmented, the resulting increase in cash flow will likely stabilize operators and encourage reinvestment. This action follows a recent executive order aimed at accelerating research into psychedelics, including psilocybin and MDMA, signaling a broader federal pivot toward the medical exploration of controlled substances.